DALY SEES 'NO URGENCY TO ADJUST THE POLICY RATE'

MNI BRIEF: Fed’s Collins Sees Rate Cuts Later Than Had Thought

MNI BRIEF: China March M2 Slows More Than Expected

MNI BRIEF: China Tightens Stock Market Supervision

MNI BRIEF: China Mar Exports Jump On Demand; Imports Improve

MNI: PBOC Sets Yuan Parity Lower At 7.0967 Fri; -4.87% Y/Y

MNI: BAKER HUGHES US RIG COUNT 617; OIL RIGS 506; GAS RIGS 109

March Home Sales Jumped At End Of Month

MNI BRIEF: Poilievre Calls QE 'Scam' And Would Limit BOC Remit

MNI: Growth Drag From Net Zero Carbon Goal Can Be Offset-OECD

MNI BRIEF: Lawmakers Signal Tough Hearing For BOC's Macklem

© 1982-2023 MNI. All rights reserved.
Terms | Privacy
Log Out
Free Trial

COVID-19 Vaccine Roundup

UK

Following the announcement of the J&J/Janssen one dose vaccine announcing a 66% efficacy rate, below is a roundup of various vaccines and their proximity to being rolled out.

  • Approved, in use: AstraZeneca/Oxford University (90% effective), Pfizer/BioNTech (95% effective)
  • Approved, awaiting distribution: Moderna (94% effective)
  • Awaiting MHRA approval: Novavax (89% effective), Janssen/J&J one-dose (66% effective)
  • In Trial: Valneva, Janssen/J&J two-dose, GSK/Sanofi (delayed)

There will be close attention paid in the UK to how the EU reacts to the Janssen news. The firm is Belgian-owned, and has its manufacturing plants there also. The UK has pre-ordered 30mn doses of the Janssen one dose vaccine (compared to 400mn from the EU, 100mn from the US and 38mn from Canada). Should theongoing row between the EU and AstraZeneca see the EU impose any form of export restriction on vaccines it could substantially limit the UK's vaccine portfolio to those produced in the country (at present AstraZeneca and the awaiting-approval Novavax vaccines).

BulletDataHomepagemarkets-real-timePolitical RiskPolitical Risk BulletMarketsFixed Income BulletsForeign Exchange Bullets

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.